Approachable Synthetic Methodologies for Second-Generation β-Lactamase Inhibitors: A Review

Area of Science:

• Medicinal Chemistry
• Microbiology
• Pharmacology

Background:

• Beta-lactam antibiotics are crucial, but their efficacy is threatened by beta-lactamase enzymes produced by bacteria.
• First-generation beta-lactamase inhibitors (BLIs) like clavulanic acid have limitations, with bacteria evolving resistance.
• A significant need exists for novel BLIs to overcome diverse and emerging resistance mechanisms.

Purpose of the Study:

• To review recent advancements in second-generation beta-lactamase inhibitors (BLIs).
• To highlight novel inhibitor classes, including metallo-beta-lactamase (MBL) and dual-nature inhibitors.
• To discuss the synthesis and clinical progress of promising BLIs developed in the last five years.

Main Methods:

• Literature review focusing on scientific publications and clinical research from the past five years.
• Analysis of novel chemical structures and mechanisms of action for second-generation BLIs.
• Evaluation of the development and synthesis strategies for various BLI classes.

Main Results:

• Second-generation BLIs demonstrate enhanced efficacy against a broader spectrum of beta-lactamases.
• Promising candidates include vaborbactam, avibactam, cyclic boronate, metallo-, and dual-nature inhibitors.
• While some BLIs are in clinical use, many advanced combinations are in preclinical or clinical research.

Conclusions:

• Second-generation BLIs represent a successful and evolving strategy against antibiotic resistance.
• Continued research and development of novel BLIs are essential to combat multidrug-resistant bacteria.
• The reviewed inhibitors show significant potential in addressing the limitations of current therapies.